Business

CSIR-IMTECH AND JOHNSON & JOHNSON ENTER INTO PARTNERSHIP FOR COLLABORATIVE RESEARCH ON NEW DRUGS FOR TUBERCULOSIS

August 16, 2017 07:43 PM

New Delhi (Face2News)

The constituent laboratory of Council of Scientific and Industrial Research (CSIR), Institute of Microbial Technology (CSIR-IMTech), today signed a MoU with global multinational healthcare company, Johnson & Johnson Private Limited. The event was presided over by Dr. Harsh Vardhan, Hon’ble Minister, Science and Technology & Earth Sciences and Vice President, CSIR.

Dr. Girish Sahni, Director General, CSIR & Secretary, DSIR briefed about CSIR R&D efforts on the occasion. Dr. Paul Stoffels, Chief Scientific Officer of Johnson & Johnson was present, along with senior members of the company’s Global Public Health unit and Sanjiv Navangul, Managing Director of Janssen India, a pharmaceutical company of Johnson & Johnson. Director of CSIR-IMTech, Dr. Anil Koul, was also present at the MoU signing ceremony. 

CSIR-IMTech is a national center for excellence in microbial Sciences and Technology. It’s vision is to discover and develop translational products and new drugs to address key unmet medical needs. The MoU between CSIR-IMTECH and Johnson and Johnson will enable collaborative research and facilitate scientists from both organizations working together on a R&D program to explore potentially more effective, safer, all-oral treatment regimens to tackle multidrug-resistant TB (MDR-TB), as well as new molecular entities to treat TB patients. 

Dr. Harsh Vardhan, on the occasion said that drug resistant TB is a global threat and a leading infectious killer in the world today. India has about one fourth of the global TB burden and sustained Research & Development efforts are needed to tackle this global scourge. He said that “India can move forward on the path of innovation and development and leverage its efforts through creating and strengthening desired partnership with industry in the domain of health research.  CSIR’s partnership with Johnson & Johnson, is a step towards that”.  He also mentioned that India has become a hub for innovation especially amongst start-ups in the Biotech Industry.

Dr. Harsh Vardhan appreciated CSIR’s efforts for pursuing cutting edge R&D in diverse domains, in particular for the affordable health care. He congratulated
Dr. Paul Stoffels and Dr. Koul for the growing partnership between Johnson & Johnson and CSIR-IMTech.

Dr. Girish Sahni, DG, CSIR said that the collaboration resonates with the Government of India's mission of ‘Swasth Bharat’ (Healthy India) and ‘Make in India’ especially for new drug discovery and development.  Over the years, CSIR has contributed significantly in the domain of affordable health care. The capacity of generic drug industry in the country which produces the cheapest drugs in the world today has been built based on CSIR’s end to end contributions. Dr. Sahni explained that the CSIR constituent Laboratories possess cutting edge knowledgebase in the domain of New Drug Development. It has developed many new drugs. CSIR has long history of working with the industry. The collaborative R&D with industry is welcome in particular for the neglected diseases. 

Elaborating on the contours of the MoU, the Director, CSIR-IMTech, Dr. Anil Koul said that collaboration with companies like Johnson & Johnson will bring a paradigm shift in drug discovery approaches for TB in India, where CSIR-IMTech will provide microbiology and medicinal chemistry expertise and Johnson & Johnson will provide its preclinical resources and drug development support. Dr. Koul also noted that the research collaboration will help support the ambitious national plan of eliminating TB by 2025. 

To mark this historical occasion, CSIR-IMTech is also organizing a “Dr. Paul Janssen TB Symposium” at Chandigarh on 17th August 2017.  Dr. Paul Stoffels, the Chief Scientific Officer, Johnson and Johnson, will be the keynote speaker at the event, and will be joined by leading clinicians, researchers and TB activists from across India.  

The symposium aims to further explore issues related to TB drug development and public policy approaches needed to address the gaps in the TB discovery pipeline.  The symposium also aims to reinforce the vision laid out by Dr. Paul Janssen, a leading scientist of this century who discovered more than 80 medicines that have benefited millions of patients across the world, and founded the Janssen Pharmaceutical companies of Johnson & Johnson.

Have something to say? Post your comment